VGA1155

01/01/2010 - "In the treatment group, a single dose of VGA1155 (1 ~ 50 mg/kg i.p.) was administrated 30 min before the induction of focal ischemia, and the vehicle group received phosphate buffer only. "
01/01/2010 - "With this dose, VGA1155 also reduced vascular permeability from 2.2 ± 0.8 µg/g to 1.2 ± 0.5 µg/g studied at 6 h after the ischemia by intravenous injection of Evans blue. "
01/01/2008 - "Brain water content and Evans Blue extravasation 24 hours after ischemia were not significantly reduced, but, compared with control group, VGA1155 significantly reduced infarct volume (32.0% for VGA1155 vs. 46.7% for control; % volume of hemisphere volume) and improved neurological function 7 days after ischemia, when tissue content of the VEGF group markedly increased to nine times that of the vehicle-treated animals. "

09/01/2004 - "VGA1155 thus exhibits promise as an antiangiogenic or anti-tumor agent with fewer side-effects."
09/01/2004 - "VGA1155 also inhibited VEGF-induced tube formation of HUVEC in vitro and tumor angiogenesis toward B16-BL6 melanoma after orthotopic implantation into the skin of the back. "
11/01/2005 - "VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model. "

09/01/2004 - "VGA1155 also inhibited VEGF-induced tube formation of HUVEC in vitro and tumor angiogenesis toward B16-BL6 melanoma after orthotopic implantation into the skin of the back. "
11/01/2005 - "VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model. "

01/01/2008 - "VGA1155 was found to protect against secondary ischemic brain damage after permanent focal cerebral ischemia, although it did not reduce vasogenic edema at 24 hours. "
01/01/2010 - "The novel VEGF receptor antagonist, VGA1155, reduces edema, decreases infarct and improves neurological function after stroke in rats."

01/01/2010 - "The data suggested that VGA1155 has antiedematous effect in acute phase after transient focal cerebral ischemia and improves neurological and histological outcomes 1 week after ischemic injury."
01/01/2010 - "The brain water content at 24 h after cerebral ischemia was significantly reduced by intraperitoneal administration of VGA1155 and the dose of 10 mg/kg showed the maximum effect on brain water content (81.8 ± 0.5% in non treated group vs. 80.2 ± 0.6% in treated group). "
01/01/2008 - "VGA1155 was found to protect against secondary ischemic brain damage after permanent focal cerebral ischemia, although it did not reduce vasogenic edema at 24 hours. "
01/01/2008 - "We examined the therapeutic effect of VGA1155 (5- [N-Methyl-N- (4-octadecyloxyphenyl) acetyl] amino-2-methyl-thiobenzoic acid), a novel small molecule antagonist of VEGF, on rat permanent focal cerebral ischemia. "
01/01/2010 - "We evaluated the effect of VGA1155 (5- [N-Methyl-N-(4-octadecyloxyphenyl)acetyl]amino-2- methylthiobenzoic acid), a novel binding antagonist of VEGF, on cerebral edema after transient focal cerebral ischemia. "